MRI measures should be a primary outcome endpoint in phase III randomized controlled trials in multiple sclerosis: No

被引：1

作者：

Ebers, George C. ^{[1
]}

机构：

[1] John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford OX3 9DU, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷 / 03期

关键词：

LONG-TERM DISABILITY; INTERFERON BETA-1B; RELAPSES;

D O I：

10.1177/1352458513518264

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：282 / 283

页数：2

共 50 条

[1] MRI measures should be a primary outcome endpoint in Phase III randomized, controlled trials in multiple sclerosis: Yes
Sormani, Maria Pia
De Stefano, Nicola
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (03) : 280 - 281
[2] MRI measures should be a primary outcome endpoint in phase III randomised controlled trials in multiple sclerosis: Commentary
Hutchinson, Michael
MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (03) : 284 - 285
[3] Should MRI be the primary endpoint of phase 3 trials in multiple sclerosis?
Rossman, Ian T.
Cohen, Jeffrey A.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (05) : 489 - 491
[4] Should MRI be the primary endpoint of phase III trials in MS? No
Weinshenker, B. G.
MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 28 - 28
[5] MRI as primary endpoint of clinical trials should MRI be the PEP of phase III trials in MS? YES
Sormani, M. P.
MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 28 - 28
[6] Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis
Bernard M. J. Uitdehaag
CNS Drugs, 2018, 32 : 543 - 558
[7] Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis
Uitdehaag, Bernard M. J.
CNS DRUGS, 2018, 32 (06) : 543 - 558
[8] Validity of brain MRI as the primary outcome criterion in multiple sclerosis phase II clinical trials
Liedtke, W
Limmroth, V
ANNALS OF NEUROLOGY, 1996, 39 (02) : 276 - 276
[9] Outcome measures in multiple sclerosis clinical trials
Andersson, PB
Goodkin, DE
BAILLIERES CLINICAL NEUROLOGY, 1997, 6 (03): : 409 - 428
[10] Outcome Measures in Clinical Trials for Multiple Sclerosis
Caspar E. P. van Munster
Bernard M. J. Uitdehaag
CNS Drugs, 2017, 31 : 217 - 236

← 1 2 3 4 5 →